Cargando…

Treatment selection of early stage non-small cell lung cancer: the role of the patient in clinical decision making

BACKGROUND: The objective of this study is to investigate the role and experience of early stage non-small cell lung cancer (NSCLC) patient in decision making process concerning treatment selection in the current clinical practice. METHODS: Stage I-II NSCLC patients (surgery 55 patients, SBRT 29 pat...

Descripción completa

Detalles Bibliográficos
Autores principales: Mokhles, S., Nuyttens, J. J. M. E., de Mol, M., Aerts, J. G. J. V., Maat, A. P. W. M., Birim, Ö., Bogers, A. J. J. C., Takkenberg, J. J. M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5769349/
https://www.ncbi.nlm.nih.gov/pubmed/29334910
http://dx.doi.org/10.1186/s12885-018-3986-5
_version_ 1783292882905464832
author Mokhles, S.
Nuyttens, J. J. M. E.
de Mol, M.
Aerts, J. G. J. V.
Maat, A. P. W. M.
Birim, Ö.
Bogers, A. J. J. C.
Takkenberg, J. J. M.
author_facet Mokhles, S.
Nuyttens, J. J. M. E.
de Mol, M.
Aerts, J. G. J. V.
Maat, A. P. W. M.
Birim, Ö.
Bogers, A. J. J. C.
Takkenberg, J. J. M.
author_sort Mokhles, S.
collection PubMed
description BACKGROUND: The objective of this study is to investigate the role and experience of early stage non-small cell lung cancer (NSCLC) patient in decision making process concerning treatment selection in the current clinical practice. METHODS: Stage I-II NSCLC patients (surgery 55 patients, SBRT 29 patients, median age 68) were included in this prospective study and completed a questionnaire that explored: (1) perceived patient knowledge of the advantages and disadvantages of the treatment options, (2) experience with current clinical decision making, and (3) the information that the patient reported to have received from their treating physician. This was assessed by multiple-choice, 1–5 Likert Scale, and open questions. The Decisional Conflict Scale was used to assess the decisional conflict. Health related quality of life (HRQoL) was measured with SF-36 questionnaire. RESULTS: In 19% of patients, there was self-reported perceived lack of knowledge about the advantages and disadvantages of the treatment options. Seventy-four percent of patients felt that they were sufficiently involved in decision-making by their physician, and 81% found it important to be involved in decision making. Forty percent experienced decisional conflict, and one-in-five patients to such an extent that it made them feel unsure about the decision. Subscores with regard to feeling uninformed and on uncertainty, contributed the most to decisional conflict, as 36% felt uninformed and 17% of patients were not satisfied with their decision. HRQoL was not influenced by patient experience with decision-making or patient preferences for shared decision making. CONCLUSIONS: Dutch early-stage NSCLC patients find it important to be involved in treatment decision making. Yet a substantial proportion experiences decisional conflict and feels uninformed. Better patient information and/or involvement in treatment-decision-making is needed in order to improve patient knowledge and hopefully reduce decisional conflict. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1186/s12885-018-3986-5) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-5769349
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-57693492018-01-25 Treatment selection of early stage non-small cell lung cancer: the role of the patient in clinical decision making Mokhles, S. Nuyttens, J. J. M. E. de Mol, M. Aerts, J. G. J. V. Maat, A. P. W. M. Birim, Ö. Bogers, A. J. J. C. Takkenberg, J. J. M. BMC Cancer Research Article BACKGROUND: The objective of this study is to investigate the role and experience of early stage non-small cell lung cancer (NSCLC) patient in decision making process concerning treatment selection in the current clinical practice. METHODS: Stage I-II NSCLC patients (surgery 55 patients, SBRT 29 patients, median age 68) were included in this prospective study and completed a questionnaire that explored: (1) perceived patient knowledge of the advantages and disadvantages of the treatment options, (2) experience with current clinical decision making, and (3) the information that the patient reported to have received from their treating physician. This was assessed by multiple-choice, 1–5 Likert Scale, and open questions. The Decisional Conflict Scale was used to assess the decisional conflict. Health related quality of life (HRQoL) was measured with SF-36 questionnaire. RESULTS: In 19% of patients, there was self-reported perceived lack of knowledge about the advantages and disadvantages of the treatment options. Seventy-four percent of patients felt that they were sufficiently involved in decision-making by their physician, and 81% found it important to be involved in decision making. Forty percent experienced decisional conflict, and one-in-five patients to such an extent that it made them feel unsure about the decision. Subscores with regard to feeling uninformed and on uncertainty, contributed the most to decisional conflict, as 36% felt uninformed and 17% of patients were not satisfied with their decision. HRQoL was not influenced by patient experience with decision-making or patient preferences for shared decision making. CONCLUSIONS: Dutch early-stage NSCLC patients find it important to be involved in treatment decision making. Yet a substantial proportion experiences decisional conflict and feels uninformed. Better patient information and/or involvement in treatment-decision-making is needed in order to improve patient knowledge and hopefully reduce decisional conflict. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1186/s12885-018-3986-5) contains supplementary material, which is available to authorized users. BioMed Central 2018-01-15 /pmc/articles/PMC5769349/ /pubmed/29334910 http://dx.doi.org/10.1186/s12885-018-3986-5 Text en © The Author(s). 2018 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research Article
Mokhles, S.
Nuyttens, J. J. M. E.
de Mol, M.
Aerts, J. G. J. V.
Maat, A. P. W. M.
Birim, Ö.
Bogers, A. J. J. C.
Takkenberg, J. J. M.
Treatment selection of early stage non-small cell lung cancer: the role of the patient in clinical decision making
title Treatment selection of early stage non-small cell lung cancer: the role of the patient in clinical decision making
title_full Treatment selection of early stage non-small cell lung cancer: the role of the patient in clinical decision making
title_fullStr Treatment selection of early stage non-small cell lung cancer: the role of the patient in clinical decision making
title_full_unstemmed Treatment selection of early stage non-small cell lung cancer: the role of the patient in clinical decision making
title_short Treatment selection of early stage non-small cell lung cancer: the role of the patient in clinical decision making
title_sort treatment selection of early stage non-small cell lung cancer: the role of the patient in clinical decision making
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5769349/
https://www.ncbi.nlm.nih.gov/pubmed/29334910
http://dx.doi.org/10.1186/s12885-018-3986-5
work_keys_str_mv AT mokhless treatmentselectionofearlystagenonsmallcelllungcancertheroleofthepatientinclinicaldecisionmaking
AT nuyttensjjme treatmentselectionofearlystagenonsmallcelllungcancertheroleofthepatientinclinicaldecisionmaking
AT demolm treatmentselectionofearlystagenonsmallcelllungcancertheroleofthepatientinclinicaldecisionmaking
AT aertsjgjv treatmentselectionofearlystagenonsmallcelllungcancertheroleofthepatientinclinicaldecisionmaking
AT maatapwm treatmentselectionofearlystagenonsmallcelllungcancertheroleofthepatientinclinicaldecisionmaking
AT birimo treatmentselectionofearlystagenonsmallcelllungcancertheroleofthepatientinclinicaldecisionmaking
AT bogersajjc treatmentselectionofearlystagenonsmallcelllungcancertheroleofthepatientinclinicaldecisionmaking
AT takkenbergjjm treatmentselectionofearlystagenonsmallcelllungcancertheroleofthepatientinclinicaldecisionmaking